Abnormalities, Multiple: Clinical Trials

6 trials for Abnormalities, Multiple, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 terminated. 6 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 16Terminated 6
Phase 23Terminated 3

Follow Abnormalities, Multiple: new trials by email Literature Review of Abnormalities, Multiple trials Research Report on Abnormalities, Multiple

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD)
ION269 - Alzheimer Disease, Down Syndrome
Phase 1TerminatedIonis Pharmaceuticals, Inc.12024-12-202026-02-20
A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome
DS-2325a, Placebo - Netherton Syndrome
Phase 1 / Phase 2TerminatedDaiichi Sankyo92023-09-282026-05-14
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
DFF332, RAD001, PDR001 - Carcinoma, Renal Cell
Phase 1TerminatedNovartis Pharmaceuticals402021-11-302026-03-03
Study of SAR421869 in Participants With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B
SAR421869 - Usher Syndrome, Retinitis Pigmentosa
Phase 1 / Phase 2TerminatedSanofi92012-03-262022-04-28
Sunitinib Malate to Treat Advanced Eye Disease in Patients With Von Hippel-Lindau Syndrome
Sunitinib Malate - Von Hippel-Lindau Syndrome
Phase 1 / Phase 2TerminatedNational Eye Institute (NEI)22008-05-012024-01-05
Serum-Free Thymus Transplantation in DiGeorge Anomaly
Serum Free Thymus Transplantation with Immunosuppression, Serum Free Thymus Transplantation without immunosuppression - DiGeorge Anomaly
Phase 1TerminatedSumitomo Pharma Switzerland GmbH22008-04-012022-04-01

Narrower conditions

von Hippel-Lindau Disease (2)  ·  Alzheimer Disease (1)  ·  Carcinoma, Renal Cell (1)  ·  DiGeorge Syndrome (1)  ·  Down Syndrome (1)  ·  Hereditary leiomyomatosis and renal cell cancer (1)  ·  Immunologic Deficiency Syndromes (1)  ·  Netherton Syndrome (1)  ·  Paraganglioma (1)  ·  Pheochromocytoma (1)  ·  Retinitis Pigmentosa (1)  ·  Thymic aplasia (1)  ·  Usher Syndromes (1)

Broader conditions

Congenital Abnormalities (6)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6)  ·  Genetic Diseases, Inborn (6)  ·  Nervous System Diseases (4)  ·  Cardiovascular Diseases (3)  ·  Angiomatosis (2)  ·  Chromosome Disorders (2)  ·  Ciliopathies (2)  ·  Neurocutaneous Syndromes (2)  ·  Neurologic Manifestations (2)  ·  Vascular Diseases (2)  ·  22q11 Deletion Syndrome (1)  ·  Adenocarcinoma (1)  ·  Blindness (1)

Interventions

Everolimus (1)  ·  Immunosuppression Therapy (1)  ·  Sunitinib (1)  ·  spartalizumab (1)

Sponsors

Daiichi Sankyo (1)  ·  Ionis Pharmaceuticals, Inc. (1)  ·  National Eye Institute (NEI) (1)  ·  Novartis Pharmaceuticals (1)  ·  Sanofi (1)  ·  Sumitomo Pharma Switzerland GmbH (1)

Countries

United States (4)  ·  France (3)  ·  Spain (2)  ·  Czechia (1)  ·  Italy (1)  ·  Japan (1)  ·  Singapore (1)

Top investigators

Catherine Meyerle, MD (1)  ·  Jose-Alain Sahel, MD, PhD (1)  ·  M. Louise Markert, M.D., Ph.D (1)  ·  Richard Weleber, MD (1)

Results publications

PMID 24705452

NIH funding

2023 (1), K12HD043494 (1), R01AI047040 (1), R01AI054843 (1)